CEOP-IMVP-Dexa regimen

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2015
0119912015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Multicentric Castleman disease (MCD) is a lymphoproliferative disorder characterized by systemic symptoms like recurrent… (More)
Is this relevant?
2015
2015
A 75-year-old man with transitional cell bladder carcinoma status post cystoprostatectomy with neobladder creation from the… (More)
  • figure 1
Is this relevant?
2012
2012
BACKGROUND Besides International Prognostic Index, many parameters have proven prognostic significance in aggressive lymphoma… (More)
Is this relevant?
2009
2009
This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
2004
2004
The main objectives of the current study were to evaluate the efficacy and safety of a CEOP-E regimen for patients with… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
1998
Review
1998
We retrospectively analyzed our chemotherapy results in patients with the Acquired Immunodeficiency Virus syndrome (AIDS) and… (More)
Is this relevant?
1997
1997
Primary end point of this trial was to reduce neutropenic infections during the treatment of aggressive NHL with CEOP/IMVP-Dexa… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1996
1996
PURPOSE This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter… (More)
Is this relevant?
1995
1995
We report on a 28 year old Turkish woman, who was admitted to our hospital with the symptoms of malabsorption and protein-loosing… (More)
Is this relevant?
1991
1991
A combination of two non-cross-resistant regimens, CEOP and IMVP-Dexa given every 4 weeks, three to six times according to… (More)
Is this relevant?